Apex Labs receives govt approval for herbal formulation to treat COVID-19


The product is available across India and is priced at Rs 11 per tablet

Apex Laboratories, a Chennai based pharmaceutical company known for its cutting-edge research and  innovation, has introduced Clevira, an antiviral herbal formulation.

Clevira was developed primarily to treat dengue patients in 2017. Last year as the COVID-19 cases surged in the country, it was repurposed as supportive treatment for mild to moderate COVID symptoms.  The product is available across India and is priced at Rs 11 per tablet.

A clinical trial was conducted on 100 people in May-June 2020 and the results were promising.  

The clinical trial results were submitted to the government of Tamil Nadu, Indian Council of Medical Research (ICMR) and Ministry of AYUSH in 2020. After rigorous scrutiny and deliberations, the drug got approval to be used as a supporting measure for treating mild to moderate COVID-19 symptoms by the Government of India (Ministry of AYUSH) regulators, a first of its kind approval in India through various stages of scrutiny at CCRAS (The Central Council for Research in Ayurvedic Sciences) and Inter-Disciplinary Technical Review Committee (ITRC),  a 12 member technical committee constituted by Ministry of AYUSH.

Karthik  Shanmugam, Head of Marketing, Apex Laboratories Pvt Ltd, said, “The drug is already available in the market across India. Moreover, it would not only compliment the allopathic treatment but also reduce the huge socioeconomic burden the country is facing now, by improving the recovery rates. We have also priced the drug affordable, so that it reaches everyone in the society.

Read Previous

Nestlé acquires core brands of The Bountiful Company for $5.7B

Read Next

2i on rise for nutraceuticals- Interest & Investment

Leave a Reply